|
|
|
|
Managing Directors |
Immanuel Thangaraj has 17 years of experience in operations and venture
capital. Mr. Thangaraj began his venture career at ARCH Venture Partners
("AVP"), a leading venture capital firm with over $1.5 billion under
management, which makes early stage technology and healthcare
investments. In his initial tenure at AVP, he managed one of its
portfolio companies, HealthQual, a medical information company, until its sale to
Nellcor, a
large hospital supplies company. In 1995, Mr. Thangaraj left AVP to run
a telecommunications company until its sale to a public company.
Mr. Thangaraj joined Essex Woodlands in 1997. He currently serves on the
Board of Directors of
CBR Systems,
Acura Pharmaceuticals (formerly
Halsey Pharmaceuticals), Clear Vascular,
Proteus,
Medlogics, and
Sound
ID. He is also responsible for Essex Woodland’s investment in
Novacept
(sold to Cytyc) and two Chinese companies, Microport
Medical and China Stem Cell.
Mr. Thangaraj holds a Bachelor of Arts and a Masters in Business
Administration from the University of Chicago. |
|
|
 |
|
|
|
